We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Merkel Cell Polyomavirus Infection Can Cause Lethal Carcinoma

By LabMedica International staff writers
Posted on 14 Jun 2016
A benign virus normally found in the skin can lead to a type of rare, lethal skin cancer; specifically, infection by the Merkel cell polyomavirus can lead to Merkel cell carcinoma in immune-compromised individuals.

Merkel cell carcinoma, which metastasizes rapidly, is one of the most aggressive skin cancers, with a mortality rate of 33%, exceeding that of melanoma, and a 45% five-year survival rate and given these dire statistics, medical professionals are keen to find better treatments.

The Merkel cell polyomavirus is an abundant virus frequently found on healthy human skin. More...
Excessive exposure to sunlight and ultraviolet radiation, immune suppression, and advanced age are the most important risk factors for Merkel cell carcinoma. Although the exact function of Merkel cells, found in the lower part of the skin epidermis, is unknown, they are thought to be nerve-associated cells involved in light touch sensation.

Scientists at the Perelman School of Medicine at the University of Pennsylvania (Philadelphia, PN, USA) have established a new way to investigate this type of oncogenic viral infection and identified a potential therapeutic agent against Merkel cell polyomavirus infection. The team discovered that the activation of special enzymes called matrix metalloproteinases by a cellular signaling pathway involving the WNT and β-catenin proteins stimulate Merkel cell polyomavirus infection.

These enzymes work in wound healing to re-engineer the skin as it heals. For example, if the skin is harmed by excessive sunlight, this stimulates the WNT/β-catenin signaling pathway, which in turn activates the metalloproteinase enzymes to be made. In the wound-healing process, these enzymes react and catalyze the extracellular matrix of affected cells. This could allow viruses to enter the cells of the dermis skin layer. Merkel cell polyomavirus (MCPyV) preferentially infected dermal fibroblasts in human skin.

The study also found that this study also found that the US Food and Drug Administration (FDA, Silver Springs, MD, USA) -approved drug trametinib for melanoma and other cancers blocks viral infection by stopping Merkel cell polyomavirus transcription and replication. Low doses of trametinib wiped out viral infection in the cell culture model developed. In addition, normal control cells were not affected by trametinib, giving hope to the fact that this drug might be able to be used with little side effects for reducing the viral load in immunocompromised patients and the goal of preventing the development of Merkel cell carcinoma.

Wei Liu, PhD, a senior postdoctoral fellow and co-author of the study, said, “Building on this novel cell culture model for Merkel cell polyomavirus infection, we would like to establish an animal model to elucidate the mechanisms by which Merkel cell polyomavirus infection leads to the highly aggressive Merkel cell carcinoma.” The study was published on June 8, 2106 in the journal Cell Host & Microbe.

Related Links:
Perelman School of Medicine at the University of Pennsylvania
US Food and Drug Administration

Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Melanoma Panel
UltraSEEK Melanoma Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.